| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Coxsackie A Antibody Panel, Complement Fixation (COXA)
Test CodeLAB2213
Quest Code
37477
CPT Codes
86658 (x6)
Includes
Coxsackie Antibodies A2, A4, A7, A9, A10, A16
Preferred Specimen
2 mL serum in gold top tube
Minimum Volume
1 mL
Other Acceptable Specimens
Plain red top tube
Transport Container
Transport tube
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 30 days
Refrigerated: 14 days
Frozen: 30 days
Methodology
Complement Fixation (CF)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Monday-sunday
Report Available
5 days
Limitations
Culture does not usually support growth of coxsackie A viruses.
Reference Range
| Coxsackie A2 Ab | <1:8 titer |
| Coxsackie A4 Ab | <1:8 titer |
| Coxsackie A7 Ab | <1:8 titer |
| Coxsackie A9 Ab | <1:8 titer |
| Coxsackie A10 Ab | <1:8 titer |
| Coxsackie A16 Ab | <1:8 titer |
Interpretive Criteria
| <1:8 | Antibody Not Detected |
| ≥1:8 | Antibody Detected |
Clinical Significance
Panel currently includes testing against A-2, 4, 7, 9, 10, and 16 antigens. Although there is cross-reactivity among the enteroviruses by CF, most healthy people do not have titers >1:8. Therefore, detectable titers, especially those >1:32, should be considered diagnostic. Confirmed serodiagnosis is made by demonstration of a four-fold change in titers between acute and convalescent sera.
Performing Laboratory
| Quest Diagnostics Nichols Institute-San Juan Capistrano, CA |
| 33608 Ortega Highway |
| San Juan Capistrano, CA 92675-2042 |
